{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:52:44Z","timestamp":1775004764015,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd015395.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000}}],"reference-count":184,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015395.pub3","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T12:02:21Z","timestamp":1701345741000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nirmatrelvir combined with ritonavir for preventing and treating COVID-19"],"prefix":"10.1002","volume":"2023","author":[{"given":"Stefanie","family":"Reis","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Cochrane Metabolic and Endocrine Disorders Group; Institute of General Practice, Medical Faculty of the Heinrich-Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kuehn","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Popp","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildiko","family":"Gagyor","sequence":"additional","affiliation":[{"name":"Department of General Practice; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kranke","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Meybohm","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne; Center for Integrated Oncology, University of Cologne; Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Weibel","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine; University Hospital W\u00fcrzburg; W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"10.1002\/14651858.CD015395.pub3-BIB0001|cit1","unstructured":"An interventional efficacy and safety, Phase 2\/3, double-blind, 2-arm study to investigate orally administered PF-07321332\/ritonavir compared with placebo in non hospitalized symptomatic adult participants with COVID-19 who are at increased risk of progressing to severe illness clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-002895-38"},{"issue":"2","key":"10.1002\/14651858.CD015395.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"ofac492.047","DOI":"10.1093\/ofid\/ofac492.047","article-title":"Effect of nirmatrelvir\/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits","volume":"9","author":"Hammond","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015395.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"ofac492.994","DOI":"10.1093\/ofid\/ofac492.994","article-title":"Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir\/ritonavir versus placebo","volume":"9","author":"Hammond","year":"2022","journal-title":"Open Forum Infectious Diseases"},{"issue":"15","key":"10.1002\/14651858.CD015395.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0005|cit5","unstructured":"EPIC-HR: study of oral PF-07321332\/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04960202"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0006|cit6","unstructured":"Soares H Baniecki ML Cardin R Leister-Tebbe H Zhu Y Guan S Viral load rebound in placebo and nirmatrelvir-ritonavir treated COVID-19 patients is not associated with recurrence of severe disease or mutations Research Square 10.21203\/rs.3.rs-1720472\/v2"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0007|cit7","unstructured":"EPIC-HR: study of oral PF-07321332\/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19 jrct.niph.go.jp\/en-latest-detail\/jRCT2031210267"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0008|cit8","unstructured":"Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study chictr.org.cn\/showproj.html?proj=167163"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.lanwpc.2023.100694","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Regional Health. Western Pacific"},{"issue":"12","key":"10.1002\/14651858.CD015395.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"22279866","DOI":"10.1101\/2022.09.12.22279866","article-title":"Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA.2\/BA2.12.1","volume":"9","author":"Aggarwal","year":"2022","journal-title":"Medrxiv"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0011|cit11","unstructured":"AGILE: seamless Phase I\/IIa platform for the rapid evaluation of candidates for COVID-19 treatment clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001860-27\/GB"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1186\/s13063-020-04473-1","article-title":"AGILE-ACCORD: a randomized, multicentre, seamless, adaptive Phase I\/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial","volume":"21","author":"Griffiths","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s13063-021-05458-4","article-title":"AGILE: a seamless phase I\/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter","volume":"22","author":"Griffiths","year":"2022","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0014|cit14","unstructured":"AGILE (Early Phase Platform Trial for COVID-19) beta.clinicaltrials.gov\/study\/NCT04746183?distance=50&term=NCT04746183&rank=1"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Nirmatrelvir and ritonavir Australian Prescriber 2022 45 2 61 10.18773\/austprescr.2022.015","DOI":"10.18773\/austprescr.2022.015"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.19163\/2307-9266-2022-10-4-371-386","article-title":"Modern directed antiviral COVID-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination","volume":"10","author":"Balykova","year":"2022","journal-title":"Pharmacy & Pharmacology"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0017|cit17","unstructured":"Open multicentre study of the safety and efficacy against COVID-19 of nirmatrelvir\/ritonavir in the adult population clinicaltrials.gov\/ct2\/show\/NCT05601167"},{"issue":"8","key":"10.1002\/14651858.CD015395.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.18553\/jmcp.2022.28.8.903","article-title":"Oral treatments for outpatient COVID-19: effectiveness and value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0019|cit19","first-page":"34","article-title":"Oral antivirals for high-risk COVID-19 patients","volume":"47","author":"Biehle","year":"2022","journal-title":"US Pharmacist"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.amjmed.2022.02.041","article-title":"Cautious optimism and considerations for health providers and patients: oral antiviral for early treatment of high-risk patients and vaccines for prevention of COVID-19","volume":"135","author":"Caceres","year":"2022","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of Covid-19","volume":"388","author":"Cao","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0022|cit22","unstructured":"A multicenter, single-blind, randomized, controlled clinical study evaluating the efficacy and safety of JT001 (VV116) compared to Paxlovid for the early treatment of coronavirus disease 2019 (COVID-19 in participants with mild to moderate COVID-19) chictr.org.cn\/showprojen.aspx?proj=167904"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0023|cit23","unstructured":"Efficacy and safety of JT001 (VV116) compared with Paxlovid clinicaltrials.gov\/ct2\/show\/NCT05341609"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0024|cit24","unstructured":"Study on the changed characteristics of glycolipid and immune metabolism in patients with coronavirus disease 2019 (COVID-19) treated by Paxlovid chictr.org.cn\/showprojEN.html?proj=169998"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0025|cit25","unstructured":"The therapeutic effect of paxlovid combined with conventional therapy in patients aged 60 and over with COVID-19 chictr.org.cn\/showprojEN.html?proj=172057"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0026|cit26","unstructured":"Efficacy evaluation of nirmatrelvir\/ritonavir tablets on SARSC-CoV-2 infection-induced myocardial injury chictr.org.cn\/showprojEN.html?proj=172892"},{"issue":"2","key":"10.1002\/14651858.CD015395.pub3-BIB0027|cit27","first-page":"27","article-title":"Paxlovid: oral antiviral for the treatment of COVID-19","volume":"166","author":"Doyno","year":"2022","journal-title":"Drug Topics"},{"issue":"5","key":"10.1002\/14651858.CD015395.pub3-BIB0028|cit28","first-page":"552A","article-title":"Nirmatrelvir\/ritonavir reduces risk of hospitalization in at-risk outpatients","volume":"105","author":"Ebell","year":"2022","journal-title":"American Family Physician"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0029|cit29","first-page":"Issue date: 15","article-title":"Nirmatrelvir and ritonavir tablets (Paxlovid)","volume":"44","author":"Elliott","year":"2022","journal-title":"Internal Medicine Alert"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.30906\/0869-2092-2022-85-7-13-22","article-title":"Pharmacological agents with antiviral activity against coronavirus SARS-CoV-2","volume":"85","author":"Enikeeva","year":"2022","journal-title":"Eksperimental'naya i Klinicheskaya Farmakologiya"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0031|cit31","unstructured":"A phase 2\/3 safety, pharmacokinetics, and efficacy study of nirmatrelvir\/ritonavir in pediatric, nonhospitalized symptomatic participants with COVID-19 who are at risk of progression to severe disease clinicaltrialsregister.eu\/ctr-search\/trial\/2022-000075-39\/HU"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/S1473-3099(22)00429-7","article-title":"Stewardship of COVID-19 volunteers by nested trial design","volume":"22","author":"Gottlieb","year":"2022","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0033|cit33","unstructured":"Paxlovid in the treatment of COVID-19 isrctn.com\/ISRCTN12428408 10.1186\/ISRCTN12428408"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0034|cit34","unstructured":"A real world study comparing the efficacy and safety of Huashi Baidu granule and paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors International Traditional Medicine Clinical Trial Registry (ccebtcm.org.cn)"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0035|cit35","unstructured":"A real world study comparing the efficacy and safety of Jingyin granule and Paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors International Traditional Medicine Clinical Trial Registry (ccebtcm.org.cn)"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0036|cit36","unstructured":"A real world study comparing the efficacy and safety of Jingyin Qinghua granule and Paxlovid in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors itmctr.ccebtcm.org.cn\/en-us\/Home\/ProjectView?pid=b54ce2cc-c2a5-4b61-8d6f-e464134d3a44"},{"issue":"17","key":"10.1002\/14651858.CD015395.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"22281161","DOI":"10.1101\/2022.10.17.22281161","article-title":"Clinical antiviral efficacy of remdesivir and casirivimab\/imdevimab against the SARS-CoV-2 Delta and Omicron variants","volume":"10","author":"Jittamala","year":"2022","journal-title":"medRxiv"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"988559","DOI":"10.3389\/fmed.2022.988559","article-title":"Can nirmatrelvir\/ritonavir treatment shorten the duration of COVID-19 isolation?","volume":"9","author":"Kim","year":"2022","journal-title":"Frontiers in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015395.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1093\/cid\/ciac600","article-title":"Association of nirmatrelvir\/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19","volume":"76","author":"Li","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0040|cit40","unstructured":"A study in non-hospitalized COVID-19 patients to assess safety and effectiveness of study drug ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=64299"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0041|cit41","unstructured":"ACTIV-2: a study for outpatients with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04518410"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0042|cit42","unstructured":"Study of PF-07321332 in healthy participants clinicaltrials.gov\/ct2\/show\/NCT04756531"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0043|cit43","unstructured":"COV-CHIM01: SARS-CoV-2 (COVID-19) dose finding infection study clinicaltrials.gov\/ct2\/show\/NCT04864548"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0044|cit44","unstructured":"A study to compare S-217622 with placebo in non-hospitalized high-risk participants with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05305547"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0045|cit45","unstructured":"A study to measure the amount of study medicine in blood in adult participants with COVID-19 and severe kidney disease clinicaltrials.gov\/ct2\/show\/NCT05487040"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0046|cit46","unstructured":"Paxlovid for treatment of long Covid clinicaltrials.gov\/ct2\/show\/NCT05576662"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0047|cit47","unstructured":"Optimisation of antiviral therapy in immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial clinicaltrials.gov\/ct2\/show\/NCT05587894"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0048|cit48","unstructured":"A decentralized Phase 2 efficacy and safety study of nirmatrelvir\/ritonavir in adult participants with long COVID clinicaltrials.gov\/ct2\/show\/NCT05668091"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0049|cit49","unstructured":"Prophylactic effect of nirmatrelvir\/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery classic.clinicaltrials.gov\/ct2\/show\/NCT05690646"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0050|cit50","unstructured":"Efficacy and safety of nirmatrelvir\/ritonavir for treating Omicron variant of COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05813600"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.24171\/j.phrp.2022.0262","article-title":"The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2","volume":"13","author":"Park","year":"2022","journal-title":"Osong Public Health and Research Perspectives"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0052|cit52","unstructured":"Adaptive platform treatment trial for outpatients with COVID-19 (ADAPT OUT COVID) ins.gob.pe\/ensayosclinicos\/rpec\/recuperarECPBNuevo.asp?numEC=084-20&val=&NroPag=1&flg=0"},{"issue":"9","key":"10.1002\/14651858.CD015395.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/ced.15281","article-title":"Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2","volume":"47","author":"Pupo Correia","year":"2022","journal-title":"Clinical and Experimental Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.healun.2023.02.1653","article-title":"Molnupiravir vs remdesivir for treatment of Covid-19 in lung transplant recipients","volume":"42","author":"Razia","year":"2023","journal-title":"Journal of Heart & Lung Transplantation"},{"issue":"7955","key":"10.1002\/14651858.CD015395.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"[3 p.]","DOI":"10.1211\/PJ.2021.1.114284","article-title":"Oral antiviral may cut risk of COVID-19 hospitalisation by nearly 90%, manufacturer claims","volume":"307","author":"Robinson","year":"2021","journal-title":"Pharmaceutical Journal"},{"issue":"7957","key":"10.1002\/14651858.CD015395.pub3-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"[3 p.]","DOI":"10.1211\/PJ.2022.1.122332","article-title":"Pfizer COVID-19 antiviral paxlovid authorised by MHRA","volume":"308","author":"Robinson","year":"2022","journal-title":"Pharmaceutical Journal"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/01.NAJ.0000890244.62778.a4","article-title":"New data on Paxlovid reported","volume":"122","author":"Rosenberg","year":"2022","journal-title":"American Journal of Nursing"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"E2220184","DOI":"10.1001\/jamanetworkopen.2022.20184","article-title":"Drug interactions with nirmatrelvir-ritonavir in older adults using multiple medications","volume":"5","author":"Ross","year":"2022","journal-title":"JAMA Network Open"},{"issue":"9","key":"10.1002\/14651858.CD015395.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3390\/vaccines10091409","article-title":"Clinical progression and outcome of hospitalized patients infected with SARS-CoV-2 Omicron variant in Shanghai, China","volume":"10","author":"Shao","year":"2022","journal-title":"Vaccines"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"22270649","DOI":"10.1101\/2022.02.08.22270649","article-title":"Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"2022.02.08","author":"Singh","year":"2022","journal-title":"medRxiv"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Singh RS Toussi SS Hackman F Chan PL Rao R Allen R Innovative randomized phase 1 study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir Clinical Pharmacology & Therapeutics 2022 112 1 101 11 10.1002\/cpt.2603","DOI":"10.1002\/cpt.2603"},{"issue":"3","key":"10.1002\/14651858.CD015395.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/v15030704","article-title":"Use of oral antivirals ritonavir-nirmatrelvir and molnupiravir in patients with multiple myeloma is associated with low rates of severe COVID-19: a single-center, prospective study","volume":"15","author":"Spiliopoulou","year":"2023","journal-title":"Viruses"},{"issue":"9","key":"10.1002\/14651858.CD015395.pub3-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"JC63","DOI":"10.7326\/J22-0038","article-title":"In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death","volume":"175","author":"Vassilopoulos","year":"2022","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7326\/M22-3057","article-title":"Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 a target trial emulation study","volume":"176","author":"Wan","year":"2023","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015395.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/jmv.27540","article-title":"In the age of omicron variant: Paxlovid raises new hopes of COVID-19 recovery","volume":"94","author":"Wang","year":"2022","journal-title":"Journal of Medical Virology"},{"issue":"2","key":"10.1002\/14651858.CD015395.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40121-023-00760-x","article-title":"Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients","volume":"12","author":"Weng","year":"2023","journal-title":"Infectious Diseases and Therapy"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"e073312","DOI":"10.1136\/bmj-2022-073312","article-title":"Nirmatrelvir and risk of hospital admission or death in adults with COVID-19: emulation of a randomized target trial using electronic health records","volume":"381","author":"Xie","year":"2023","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD015395.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"619","DOI":"10.21037\/atm-22-2791","article-title":"The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6\u201314 years: a cohort study","volume":"10","author":"Yan","year":"2022","journal-title":"Annals of Translational Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"1147980","DOI":"10.3389\/fphar.2023.1147980","article-title":"Nirmatrelvir\/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge","volume":"14","author":"Yan","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0071|cit71","unstructured":"A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 clinicaltrialsregister.eu\/ctr-search\/trial\/2022-002447-22\/BG"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0072|cit72","unstructured":"A study to learn about the medicine called nirmatrelvir used in combination with ritonavir in people with weakened immune systems or at increased risk for poor outcomes who are hospitalized due to severe COVID-19 (EPIC-HOS) clinicaltrials.gov\/ct2\/show\/NCT05545319"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0073|cit73","unstructured":"A phase 2\/3 postexposure prophylaxis study of PF-07321332\/ritonavir in household contacts of a patient with COVID-19 clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-002894-24"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0074|cit74","unstructured":"A post-exposure prophylaxis study of PF-07321332\/ritonavir in adult household contacts of an individual with symptomatic COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05047601"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0075|cit75","unstructured":"A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection jrct.niph.go.jp\/en-latest-detail\/jRCT2031210349"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0076|cit76","unstructured":"A phase 2\/3 efficacy and safety study of PF-07321332\/ritonavir in nonhospitalized low-risk adult participants with COVID-19 clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-002857-28"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0077|cit77","unstructured":"A study of PF-07321332\/ritonavir in non-hospitalized low-risk adult participants with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05011513"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0078|cit78","unstructured":"A study of PF-07321332\/ritonavir in non-hospitalized low-risk adult participants with COVID-19 jrct.niph.go.jp\/en-latest-detail\/jRCT2031210274"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0079|cit79","unstructured":"A study to learn about the study medicines called nirmatrelvir\/ritonavir in people at least 12 years of age with COVID-19 who are immunocompromised clinicaltrialsregister.eu\/ctr-search\/trial\/2022-001362-35\/BG"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0080|cit80","unstructured":"A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors chictr.org.cn\/showproj.aspx?proj=169088"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0081|cit81","unstructured":"Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200059726"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0082|cit82","unstructured":"A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200059739"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0083|cit83","unstructured":"Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200060010"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0084|cit84","unstructured":"Finding treatments for COVID-19: a trial of antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV) clinicaltrials.gov\/ct2\/show\/NCT05041907"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0085|cit85","unstructured":"Adaptive, randomized, non-inferiority trial on the use of monoclonal antibodies or antivirals in outpatients with mild or moderate COVID-19 clinicaltrials.gov\/ct2\/show\/NCT05321394?term=NCT05321394&draw=2&rank=1"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0086|cit86","unstructured":"Paxlovid in the treatment of COVID-19 patients with uremia clinicaltrials.gov\/ct2\/show\/NCT05386433"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0087|cit87","unstructured":"A study to learn about a repeat 5-day treatment with nirmatrelvir\/ritonavir in people with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir\/ritonavir clinicaltrialsregister.eu\/ctr-search\/trial\/2022-002447-22\/SK"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0088|cit88","unstructured":"A study to learn about a repeat 5-day treatment with the study medicines (called nirmatrelvir\/ritonavir) in people 12 years old or older with return of COVID-19 symptoms and SARS-CoV-2 positivity after finishing treatment with nirmatrelvir\/ritonavir clinicaltrials.gov\/ct2\/show\/NCT05567952"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0089|cit89","unstructured":"Canadian adaptive platform trial of treatments for COVID in community settings (CanTreatCOVID) clinicaltrials.gov\/ct2\/show\/NCT05614349"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0090|cit90","unstructured":"The efficacy of azvudine and Paxlovid in high-risk patients with COVID-19: a prospective randomized controlled trial clinicaltrials.gov\/ct2\/show\/NCT05642910"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0091|cit91","unstructured":"A clinical trial investigating novel treatments for COVID-19 in the community isrctn.com\/ISRCTN30448031"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0092|cit92","unstructured":"Randomised evaluation of COVID-19 therapy (RECOVERY) clinicaltrials.gov\/ct2\/show\/NCT04381936"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12875-021-01606-6","article-title":"Willingness, beliefs, and barriers regarding the COVID-19 vaccine in Saudi Arabia: a multiregional cross-sectional study","volume":"22","author":"Altulahi","year":"2021","journal-title":"BMC Family Practice"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"115860","DOI":"10.1016\/j.bmc.2020.115860","article-title":"Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors","volume":"29","author":"Amin","year":"2021","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"5626","key":"10.1002\/14651858.CD015395.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines \u2013 3: rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015395.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e0247461","DOI":"10.1371\/journal.pone.0247461","article-title":"Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis","volume":"16","author":"Booth","year":"2021","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/medethics-2020-106494","article-title":"The carnage of substandard research during the COVID-19 pandemic: a call for quality","volume":"46","author":"Bramstedt","year":"2020","journal-title":"Journal of Medical Ethics"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0100|cit100","unstructured":"Centers for Disease Control and Prevention (CDC) Benefits of getting a COVID-19 vaccine cdc.gov\/coronavirus\/2019-ncov\/vaccines\/vaccine-benefits.html"},{"issue":"2","key":"10.1002\/14651858.CD015395.pub3-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"e28471","DOI":"10.1002\/jmv.28471","article-title":"Nirmatrelvir\u2013ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"95","author":"Cheema","year":"2023","journal-title":"Journal of Medical Virology"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13238-010-0011-4","article-title":"Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0103|cit103","unstructured":"Cochrane Database of Systematic Reviews: editorial policies. Cochrane policy on managing potentially problematic studies cochranelibrary.com\/cdsr\/editorial-policies#problematic-studies"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0104|cit104","unstructured":"Core Outcome Measures in Effectiveness Trials (COMET) Initiative Core outcome set developers' response to COVID-19 comet-initiative.org\/Studies\/Details\/1538"},{"issue":"6497","key":"10.1002\/14651858.CD015395.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0106|cit106","unstructured":"Cochrane Pregnancy and Childbirth Group pcg_data_extraction_form_v_2.2_-_13_july_2021_1.docx pregnancy.cochrane.org\/author-resources-new-reviews (website is no longer available)"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1101\/2020.08.28.272880","article-title":"Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models","volume":"95","author":"Vries","year":"2020","journal-title":"bioRxiv"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0108|cit108","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013705.pub3","article-title":"Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection","author":"Dinnes","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0110|cit110","unstructured":"EndNote Clarivate 2013"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0111|cit111","unstructured":"Fact sheet for healthcare providers: emergency use authorization for Paxlovid www.fda.gov\/media\/155050\/download"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41467-020-19057-5","article-title":"SARS-CoV-2 viral load is associated with increased disease severity and mortality","volume":"11","author":"Fajnzylber","year":"2020","journal-title":"Nature Communications"},{"issue":"11","key":"10.1002\/14651858.CD015395.pub3-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013652.pub2","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2","author":"Fox","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD015395.pub3-BIB0114|cit114","first-page":"2100348","article-title":"Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021","volume":"26","author":"Funk","year":"2021","journal-title":"Euro Surveillance"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jebm.12444","article-title":"Integrating Chinese and Western medicine for COVID-19: a living evidence-based guideline (version 1)","volume":"14","author":"Ge","year":"2021","journal-title":"Journal of Evidence Based Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0116|cit116","unstructured":"Blankenfeld H Kaduszkiewicz H Kochen MM P\u00f6msl J SARS-CoV-2\/Covid-19 Informationen und Praxishilfen f\u00fcr niedergelassene Haus\u00e4rztinnen und Haus\u00e4rzte awmf.org\/leitlinien\/detail\/ll\/053-054.html"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"e0234765","DOI":"10.1371\/journal.pone.0234765","article-title":"The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries","volume":"15","author":"Grant","year":"2020","journal-title":"PLOS One"},{"issue":"12","key":"10.1002\/14651858.CD015395.pub3-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7789","key":"10.1002\/14651858.CD015395.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/d41586-019-03959-6","article-title":"Check for publication integrity before misconduct","volume":"577","author":"Grey","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1002\/14651858.CD015395.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nature Reviews Microbiology"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0121|cit121","unstructured":"Higgins JP Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological Expectations of Cochrane Intervention Reviews (MECIR) community.cochrane.org\/mecir-manual\/"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0122|cit122","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0123|cit123","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"10223","key":"10.1002\/14651858.CD015395.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"10270","key":"10.1002\/14651858.CD015395.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"12","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"11","key":"10.1002\/14651858.CD015395.pub3-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S1473-3099(21)00558-2","article-title":"Hospitalisation among vaccine breakthrough COVID-19 infections","volume":"21","author":"Juthani","year":"2021","journal-title":"Lancet Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD015395.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","article-title":"Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study","volume":"8","author":"Karagiannidis","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"12","key":"10.1002\/14651858.CD015395.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"e0243597","DOI":"10.1371\/journal.pone.0243597","article-title":"Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients","volume":"15","author":"Kawasuji","year":"2020","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"790","DOI":"10.15585\/mmwr.mm6925e1","article-title":"Characteristics associated with hospitalization among patients with COVID-19 \u2013 Metropolitan Atlanta, Georgia, March\u2013April 2020","volume":"69","author":"Killerby","year":"2020","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12967-020-02520-8","article-title":"Pathophysiology and treatment strategies for COVID-19","volume":"18","author":"Kumar","year":"2020","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0133|cit133","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa2117128","article-title":"Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina","volume":"386","author":"Lin","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","article-title":"Viral dynamics in mild and severe cases of COVID-19","volume":"20","author":"Liu","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015395.pub3-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0137|cit137","unstructured":"Meta: General Package for Meta-Analysis Schwarzer G The R Project 2022"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/bmjebm-2022-112019","article-title":"Pragmatic and open science-based solution to a current problem in the reporting of living systematic reviews","volume":"28","author":"Metzendorf","year":"2023","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0139|cit139","unstructured":"Medicines Patent Pool medicinespatentpool.org\/who-we-are\/about-us"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0140|cit140","unstructured":"Nirmatrelvir \u2013 license agreement; November 2021 Available at medicinespatentpool.org\/licence-post\/pf-07321332"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0141|cit141","unstructured":"ACTIV-3: Therapeutics for Inpatients with COVID-19 (TICO) clinicaltrials.gov\/ct2\/show\/NCT04501978"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0142|cit142","unstructured":"First-in-human study to evaluate safety, tolerability, and pharmacokinetics following single ascending and multiple ascending doses of PF-07304814 in hospitalized participants with COVID-19 clinicaltrials.gov\/ct2\/show\/NCT04535167"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0143|cit143","unstructured":"National Health Service (NHS) UK Who cannot have vaccines nhs.uk\/conditions\/vaccinations\/why-vaccination-is-safe-and-important\/"},{"issue":"6575","key":"10.1002\/14651858.CD015395.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"24","key":"10.1002\/14651858.CD015395.pub3-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"m1966","DOI":"10.1136\/bmj.m1966","article-title":"Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study","volume":"369","author":"Petrilli","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0147|cit147","unstructured":"Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2\/3 EPIC-HR study pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0148|cit148","unstructured":"Potentially significant drug interactions, including contraindicated drugs PAXLOVID TM (nirmatrelvir tablets; ritonavir tablets) pfizermedical.pfizerpro.com\/api\/vc\/en\/medical\/assets\/5773bb0d-ab2b-40bb-8988-be557bd70923\/Potentially%20Significant%20Drug%20Interactions.pdf"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0149|cit149","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015025","article-title":"Antibiotics for the treatment of COVID-19","author":"Popp","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015017.pub3","article-title":"Ivermectin for preventing and treating COVID-19","author":"Popp","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0151|cit151","unstructured":"Reis S Metzendorf M Kuehn R Popp M Gagyor I Kranke P Living evidence base for Cochrane Review \"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19\" osf.io\/7g49c\/ 10.17605\/OSF.IO\/7G49C"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","article-title":"Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance","volume":"10","author":"Ren","year":"2022","journal-title":"World Journal of Clinical Cases"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0153|cit153","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 spike protein: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0155|cit155","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12939-020-01218-z","article-title":"Health equity and COVID-19: global perspectives","volume":"19","author":"Shadmi","year":"2020","journal-title":"International Journal for Equity in Health"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0158|cit158","unstructured":"Weibel S Reis S Supplementary File_Nirmatrelvir_Research Integrity Assessment (Version 2) Zenodo 2023 10.5281\/zenodo.10117597"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0159|cit159","unstructured":"Weibel S Reis S Supplementary File_Nirmatrelvir_Risk of Bias Excel Tool (Version 2) Zenodo 2023 10.5281\/zenodo.10102195"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against COVID-19 Omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"e28732","DOI":"10.1002\/jmv.28732","article-title":"Nirmatrelvir\u2013ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"95","author":"Tian","year":"2023","journal-title":"Journal of Medical Virology"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"6","key":"10.1002\/14651858.CD015395.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1002\/14651858.CD015395.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.vaccine.2021.04.020","article-title":"Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: a national cross-sectional study","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"m1808","DOI":"10.1136\/bmj.m1808","article-title":"Interpreting a COVID-19 test result","volume":"369","author":"Watson","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0166|cit166","doi-asserted-by":"crossref","unstructured":"Weibel S Popp M Reis S Skoetz N Garner P Sydenham E Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis www.medrxiv.org\/content\/10.1101\/2022.05.31.22275756v1 10.1101\/2022.05.31.22275756","DOI":"10.1101\/2022.05.31.22275756"},{"issue":"10","key":"10.1002\/14651858.CD015395.pub3-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"e1001333","DOI":"10.1371\/journal.pmed.1001333","article-title":"PRISMA-Equity 2012 Extension: reporting guidelines for systematic reviews with a focus on health equity","volume":"9","author":"Welch","year":"2012","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0168|cit168","unstructured":"World Health Organization (WHO) International standards for clinical trial registries \u2013 2nd edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO Available at www.who.int\/publications\/i\/item\/international-standards-for-clinical-trial-registers"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0169|cit169","unstructured":"World Health Organization (WHO) Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) who.int\/docs\/default-source\/coronaviruse\/who-china-joint-mission-on-covid-19-final-report"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0170|cit170","unstructured":"World Health Organization (WHO) Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief apps.who.int\/iris\/handle\/10665\/331713"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0171|cit171","unstructured":"World Health Organization (WHO) WHO coronavirus disease (COVID-19) dashboard covid19.who.int\/table"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0172|cit172","unstructured":"World Health Organization (WHO) Vaccine equity who.int\/campaigns\/vaccine-equity"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0173|cit173","unstructured":"World Health Organization (WHO) Therapeutics and COVID-19: living guideline app.magicapp.org\/#\/guideline\/nBkO1E\/rec\/E850m0 version 6 15 23"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0174|cit174","unstructured":"World Health Organization (WHO) COVID-19 weekly epidemiological update. Edition 148. Published 22 June 2023 who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---22-june-2023"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0175|cit175","unstructured":"Therapeutics and COVID-19: living guideline www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2023.1"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0176|cit176","unstructured":"Drugs to prevent COVID-19: living guideline www.who.int\/publications\/i\/item\/WHO-2019-nCoV-prophylaxes-2023.1"},{"issue":"7821","key":"10.1002\/14651858.CD015395.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0178|cit178","unstructured":"The world by income and region datatopics.worldbank.org\/world-development-indicators\/the-world-by-income-and-region.html"},{"issue":"13","key":"10.1002\/14651858.CD015395.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015395.pub3-BIB0180|cit180","unstructured":"Xu Y Chen Y Tang X Guidelines on the diagnosis and treatment of COVID-19 ninth trial edition www.gov.cn\/zhengce\/zhengceku\/2022-03\/15\/5679257\/files\/49854a49c7004f4ea9e622f3f2c568d8.pdf"},{"issue":"6489","key":"10.1002\/14651858.CD015395.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD015395.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/acs.jproteome.0c00526","article-title":"Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication","volume":"20","author":"Zhang","year":"2021","journal-title":"Journal of Proteome Research"},{"issue":"4","key":"10.1002\/14651858.CD015395.pub3-BIB0183|cit183","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015395","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","author":"Reis","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015395.pub3-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015395.pub2","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","author":"Reis","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T03:34:47Z","timestamp":1746675287000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015395.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":184,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015395.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}